| Name | Title | Contact Details |
|---|
Nano-C is a Westwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Enzo Life Sciences is a wholly owned subsidiary of Enzo Biochem headquartered in Farmingdale, New York. Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and therapeutics through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products systems and services that meet the ever-changing and rapidly growing needs of healthcare both today and into the future. Underpinning Enzo Biochem’s technologies, platforms and products is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies. Enzo Life Sciences is a pioneer in labeling and detection technologies from DNA to whole cell across research and diagnostic markets. We are focused on providing cost-effective, relevant and reliable solutions for life science research, drug development, and clinical research. We are organized to lead in the development, production, marketing, and sales of innovative research tools worldwide based on 40 years’ experience in building strong global market recognition and implementing outstanding operational capabilities. Our strong portfolio of proteins, antibodies, peptides, small molecules, labeling probes, dyes and kits provides researchers tools for target identification/validation, high content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis."
Our mission is to make actionable information accessible to everyone at the time it matters. By making actionable information accessible to everyone in the world at the time it matters most, we are working to facilitate the early detection and prevention of disease, and empower people everywhere to live their best possible lives.
BioShield Technologies is a Norcross, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Protagonist Therapeutics is a biotechnology company pursuing the discovery and development of target oral peptides as well differentiated alternatives to antibodies, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which suitable small molecule and/or biologic options are not available. Peptides typically suffer from limitations of poor proteolytic stability and therefore find scarce therapeutic utility that is largely limited to ‘injectable drugs’. Protagonist’s technology platform is aimed at overcoming these restrictions and expanding the scope of peptide therapeutics to address unmet needs. Specific emphasis is placed on identifying ‘orally stable’ scaffolds and/or engineering oral stability characteristics onto them. The platform has been optimized over the years and involves synergistic integration of rational drug design, diversity oriented computational tools, phage display libraries, recombinant peptide expression, ex vivo oral stability methods, and peptide/medicinal chemistry techniques. This activity has led to the identification of ‘privileged scaffolds’ with favorable oral stability characteristics. Furthermore, the technology platform is well suited both for de novo discovery against a target and optimization around a given chemical starting point.